CHBOF (China Health Technology Group Holding Co) Beta: N/A (As of Jun. 26, 2026)


CHBOF China Health Technology Group Holding Co Ltd CHBOF
25 GF Score
Price $0.03
GF Value $0.07
! 7 Warning Signs
View Full Analysis

What is China Health Technology Group Holding Co Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), China Health Technology Group Holding Co's Beta is Not available.

China Health Technology Group Holding Co  (OTCPK:CHBOF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

China Health Technology Group Holding Co Beta Related Terms

China Health Technology Group Holding Co Beta Historical Data

* Premium members only.

The historical data trend for China Health Technology Group Holding Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Health Technology Group Holding Co Beta Chart

China Health Technology Group Holding Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

China Health Technology Group Holding Co Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHBOF
25GF Score
China Health Technology Group Holding Co Ltd CHBOF
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Health Technology Group Holding Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is China Health Technology Group Holding Co (CHBOF) Overvalued in 2026?

Based on GuruFocus' analysis, China Health Technology Group Holding Co stock appears to be undervalued. The current stock price of $0.03 is trading 52.9% below its estimated GF Value™ of $0.07.

Key valuation signals for CHBOF:

  • Beta: N/A
  • GF Value™: $0.07 vs. price of $0.03 (52.9% below fair value)
  • GF Score™: 25/100 with 7 warning signs

No single metric tells the full story. See the CHBOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Health Technology Group Holding Co Business Description

Other Exchanges 01069:Hong Kong
Address South Binhe Avenue, Room 4903, Building A, West Tower, C Future City, Futian District, Shenzhen, CHN
China Health Technology Group Holding Co Ltd is an investment holding company. It is engaged in the business of management of new agriculture and forestry resources in the People's Republic of China. The company has reportable segments including the Forestry business; Horny Goat Weed Business; Health products business and Ginseng Business. The forestry management business includes plantation, logging, and sale of timber-related products and the Ginseng Business includes ginseng plantation and trading of related products. The company generates a majority of its revenue from the Forestry business segment. Geographically company generates its key revenue from the PRC.
25GF Score

Get the complete analysis for CHBOF

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.03
Price
$0.07
GF Value